Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.
Allen, Carl E
Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. [electronic resource] - Blood 09 2018 - 1438-1451 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
1528-0020
10.1182/blood-2018-01-828277 doi
Adolescent
Adult
Alemtuzumab--therapeutic use
Antineoplastic Agents--therapeutic use
Child
Child, Preschool
Female
Graft vs Host Disease--prevention & control
Hematopoietic Stem Cell Transplantation--methods
Humans
Infant
Lymphohistiocytosis, Hemophagocytic--therapy
Male
Melphalan--therapeutic use
Survival Analysis
Transplantation Conditioning--methods
Treatment Outcome
Vidarabine--analogs & derivatives
Young Adult
Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. [electronic resource] - Blood 09 2018 - 1438-1451 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
1528-0020
10.1182/blood-2018-01-828277 doi
Adolescent
Adult
Alemtuzumab--therapeutic use
Antineoplastic Agents--therapeutic use
Child
Child, Preschool
Female
Graft vs Host Disease--prevention & control
Hematopoietic Stem Cell Transplantation--methods
Humans
Infant
Lymphohistiocytosis, Hemophagocytic--therapy
Male
Melphalan--therapeutic use
Survival Analysis
Transplantation Conditioning--methods
Treatment Outcome
Vidarabine--analogs & derivatives
Young Adult